(Total Views: 609)
Posted On: 11/05/2020 2:40:14 PM
Post# of 148902
Re: Lee Ron Lemab #64246
RLFTF update if anyone cares while we're waiting
They announced today that after interim look for efficacy at 102 patients, the data monitoring committee recommended to continue the trial to completion with 165 patients. The final data should be ready mid-Jan. So they arguably didn't get as good of a recommendation as we did, although with their smaller trial size a 75% interim probably wouldn't make much difference.
Again I'll say it's an utter travesty that leronlimab, lenzilumab and RLF-100 have all shown promise as treatments for covid yet the FDA has not taken the steps to expedite approval. It's ridiculous that the FDA has not demanded to look at the interim analyses for these trials to check for efficacy because interim results could be above what's needed for stopping the trial yet clearly be below a 0.05 p-value, thus essentially effective.
I did buy back in to RLFTF yesterday, I've been in and out a couple of times, but sold at a profit today. Maybe I'll get back in at some point.
They announced today that after interim look for efficacy at 102 patients, the data monitoring committee recommended to continue the trial to completion with 165 patients. The final data should be ready mid-Jan. So they arguably didn't get as good of a recommendation as we did, although with their smaller trial size a 75% interim probably wouldn't make much difference.
Again I'll say it's an utter travesty that leronlimab, lenzilumab and RLF-100 have all shown promise as treatments for covid yet the FDA has not taken the steps to expedite approval. It's ridiculous that the FDA has not demanded to look at the interim analyses for these trials to check for efficacy because interim results could be above what's needed for stopping the trial yet clearly be below a 0.05 p-value, thus essentially effective.
I did buy back in to RLFTF yesterday, I've been in and out a couple of times, but sold at a profit today. Maybe I'll get back in at some point.
(2)
(0)Scroll down for more posts ▼
